Abstract: The invention provides compositions comprising chitosan, manuka honey and one or more additional components that promotes digestive health (e.g., inulin, probiotics) for the treatment and prevention of gastric ulcers (esophageal, stomach, or duodenum) in a mammal (e.g., equine).

Abstract: A pharmaceutical formulation is disclosed which includes at least: (1) elagolix sodium, (2) magnesium oxide, and (3) at least one disintegrating agent, such as crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized and mixtures thereof. A tablet is also disclosed which includes a tablet core formed from the pharmaceutical formulation. The elagolix sodium tablets of the present disclosure display improved dissolution rates when tested using for example the Tablet Sink Time test. The tablets also exhibit improved storage stability of the elagolix sodium, with a reduction in degradation products during storage.

Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

Abstract: A composition for cosmetics is provided, which has a UV shielding effect and which can produce a cosmetic having good dispersibility, an excellent UV shielding effect and excellent use feeling, cosmetic effect, long-lasting cosmetic performance. The cosmetic obtained by using the same is provided. The composition for cosmetics includes (A) microparticulate titanium dioxide, (B) one kind or two or more kinds of magnesium hydroxide and calcium hydroxide. The composition for cosmetics preferably contains further (C) a clay mineral. The compounding weight ratio among (A): (B): (C) is preferably 20 to 60: 3 to 40: 0 to 77. In addition, the composition for cosmetics is preferably one in which a mixed powder of (A), (B) and (C) is lipophilically treated.

Abstract: The invention provides compositions for the prevention and treatment of the symptoms of alcoholic beverage-induced hangover syndrome, related kits and methods of using the compositions and kits.

Abstract: Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C.

Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: The present invention relates to the field of food and medicines for the treatment or alleviation of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), premenopause, menopause and female hormonal disorders. A first embodiment relates to a composition containing vitamins, minerals and oils. Additionally, the invention comprises a pharmaceutical form, more specifically in the form of soft capsules (also known as gelatin) containing the composition of the invention. In particular, the compositions of the invention contain vitamins and minerals in sources compatible with the association of vegetable oils, preferably borage oil, evening primrose oil, or a mixture of two oils, wherein the soft capsule contains a liquid and oily core.

Abstract: To provide a plant disease controlling agent and the method for controlling plant diseases using the same, the plant disease controlling agent being commonly applicable to various crop and soil conditions, and ensures safety over a long period throughout the environment. Provided is a plant disease controlling agent including magnesium oxide obtained by baking magnesium hydroxide at 400 to 1000° C. Further, provided is a method for controlling plant diseases using the plant disease controlling agent. The method is preferably any of mixing the plant disease controlling agent with the surface soil, mixing the plant disease controlling agent with the nursery soil, treating foliage with an aqueous suspension of the plant disease controlling agent, immersing plant roots in the plant disease controlling agent, and irrigating plant feet with the plant disease controlling agent.

Abstract: A composition including a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH)2, at a concentration ranging from 0 to 99 wt %; or Mg(OH)2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.

Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.

Abstract: An enhanced article which has a beneficial contact surface intended to allow bioabsorption of beneficial materials through the user's contact with the enhanced article in use. A functional or ornamental article which has at least one contact surface intended to come in contact with a human user includes a beneficial contact surface for covering the article's contact surface and providing a beneficial surface contact compound adapted to come in contact with a human user touching the article. The beneficial contact surface is connected to the article so that the contact surface of the article is covered by the beneficial contact surface. The presence of the beneficial surface contact compound in the beneficial contact surface means results in the exposure of the user's skin to the beneficial surface contact compound to allow absorption by the user.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: The present invention relates to development of bioactive glass/glass-ceramic composition that are able to promote a fast deposition layer of carbonated hydroxyapatite upon immersion in simulated body fluid (SBF) for time periods as short as one hour. Such composition might include fluorides, and a variety of oxides (or their precursor compounds), such as Na2O—Ag2O—SrO—CaO—MgO—ZnO—P2O5—SiO2—Bi2O3—B2O3—CaF2, be prepared by the melt route or by the sol-gel process, with the specific composition and the preparation route selected according to the intended functionalities, which can present controlled biodegradation rate and bactericidal activity. The powders derived from glass melts purred in cold water (frits) may completely densify by sintering at temperatures up to 800° C. without devitrification, resulting in bioglass compacts with high flexural strength (˜85 MPa). The bioactive glass powders prepared by sol-gel densify at lower temperatures due to their higher specific surface area and reactivity.

Abstract: One or more particles of bioactive glass coated with a glycosaminoglycan, wherein the glycosaminoglycan is bound to the bioactive glass and methods of treatment using such particles.

Abstract: An orally administered composition that includes least one alkaline agent with a pH of at least 9.0 to 12.0, mixed in an aqueous vehicle with relatively high surface tension, high viscosity and lateral adhesion properties. When mixed, a low water soluble emulsion is formed that evenly coats and partially adheres to the lower section of the esophagus and the LES and forms a relatively long acting, protective barrier and partially neutralizes gastric acid. In one embodiment, the alkaline agent is potassium hydroxide and the aqueous vehicle is made of hydroxypropyl methyl cellulose, polyethylene glycol or ethylene glycol and additional thickener agents capable of withstanding high pH environments, such as xanthan gum, croscarmellose sodium, and microcrystalline cellulose. Additional organoleptic agents, such as gum Arabic and polyethylene glycol, flavorings, such as sodium chloride, acesulfame potassium, sodium saccharine, and mint, and stabilizers such as colloidal silica made be added.

Abstract: A novel dietary supplement and methods for manufacturing the said dietary supplement are disclosed for promoting healthy cartilages, connective tissues and bones. The dietary supplement of the present invention comprises glucosamine hydrochloride, collagen, and other dietary ingredients. Some ingredients of the dietary supplement of the present invention help to maintain the functions of cartilages, connective tissues and bones. Some ingredients of the dietary supplement of the present invention also exhibit anti-inflammatory properties. Overall, these ingredients of the dietary supplement are beneficial to the health of human and other animals.

Abstract: Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.

Abstract: The subject matter of the invention relates to the use of a composition comprising at least one oxide and/or hydroxide insoluble in an aqueous environment, preferably selected from silicon dioxide (SlO2), titanium dioxide (TlO2), aluminium oxide (AI2O3) and aluminium hydroxide (Al(OH)3), magnesium oxide (MgO), to reduce absorption of the ethanol ingested through the consumption of alcoholic beverages. The invention also comprises the use of food products comprising these mixtures for the aforesaid use.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.

Abstract: A phase change formulation includes a reversible phase change material and a thermal conductivity additive formulated for application to a user's epidermis.

Abstract: Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH)2 (a strong adsorbent for arsenic) doped with a divalent or trivalent metal cation is used to adsorb arsenic. The complex consisting of arsenic adsorbed on Mg(OH)2 doped with a divalent or trivalent metal cation is subsequently removed from the water by conventional means, including filtration, settling, skimming, vortexing, centrifugation, magnetic separation, or other well-known separation systems. In another embodiment, magnesium oxide, MgO, is employed, which reacts with water to form Mg(OH)2. The resulting Mg(OH)2 doped with a divalent or trivalent metal cation, then adsorbs arsenic, as set forth above. The method can also be used to treat human or animal poisoning with arsenic.

Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Abstract: The invention concerns a product for the upper gastric sphere of humans. The product can address acidity in upper gastric sphere of humans. The product of the invention is typically to be administered orally, typically as food or food supplement. The product comprises a base product and several agents that provide benefits to the upper gastric sphere.

Abstract: The use of humic acids, zeolites, magnesium oxide beads and other mineral-containing materials in the activation of ethanol, alcoholic beverages and water is disclosed. Consumption of the energized liquids can have therapeutic benefits. The activated ethanol can be further used with neutral red dye and ultraviolet (UV) light illumination to indirectly enhance the environmental energy absorption properties of other liquids, including drinking water and of mineral containing materials. Mineral activated ethanol can similarly be used with neutral red dye and UV illumination to enhance the alternative cellular energy (ACE) pathway of an individual.

Abstract: Nutritional compositions having the potential to reduce metabolic acid load and methods of making and using the nutritional compositions are provided. In an embodiment, the present disclosure provides methods of selecting and administering nutritional compositions to patients. The methods may include modifications to calculating a metabolic acid potential of a nutritional composition, calculating a base content of a nutritional composition and subtracting the base content from the acid content to determine a potential renal acid load (“PRAL”) value. The present disclosure also provides computer implemented processes for predicting PRAL values.

Abstract: There is disclosed therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, containing a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material. Also disclosed is the use of a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material in the preparation of therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, in particular, orthodontic devices, glasses and plasters.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: Based on the present disclosure, a minimal time interval can be achieved between the last ingestion of a picosulfate composition and the performance of the colonoscopy. For example, the present disclosure is directed to a method of timing a colonoscopy procedure performed on a patient in need thereof, comprising: administering, to the patient, a picosulfate bowel composition kit according to the kit's instructions; performing the procedure less than about 4 hours after the administration of the kit.

Abstract: An embodiment of the present invention relates to a therapeutically active composition for the treatment of arteriosclerosis, and a pharmacological active agent-releasing medical device, the efficiency of which is increased by combination with a compound that releases alkaline-earth metal ions.

Abstract: A stable, phase-pure magnesium-substituted crystalline hydroxyapatite containing from about 2.0 to about 29 wt % magnesium, wherein at least 75 wt % of the magnesium content is substituted for calcium ions in the hydroxyapatite lattice structure.

Abstract: Of the many compositions and methods provided herein, one composition includes a nanoparticle having a first oxide of a first metal and a dopant that includes an ion or an atom of a second metal. A method includes a method comprising providing a plurality of nanoparticles comprising a first oxide of a first metal and a dopant that comprises an ion or an atom of a second metal; providing a diseased cell and a healthy cell; contacting the diseased cell and the healthy cell with the nanoparticle; and allowing the nanoparticle to preferentially associate with the diseased cell.

Abstract: A beverage for minimizing or reducing jet lag symptoms preferably includes vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin D, zinc, calcium, iodine, magnesium, manganese, ginseng, ginkgo biloba, grape seed extract, Echinacea extract and water. A method for minimizing or reducing jet lag symptoms including ingestion of the beverage by a traveler, one hour prior to a flight, and/or during the flight, and/or after a flight.

Abstract: The present invention relates to improved methods of preventing or inhibiting the release of acid in the stomach, which are uniquely reversible at the cellular level, through the use of organic isothiocyanates and thiocyanates with divalent cations such as barium, zinc and calcium for human and veterinary applications. The present invention also relates to methods of preventing or treating persistent chronic gastritis, GERDs, ulcer and or stomach cancer by inhibiting the release of stomach acid and by reducing inflammation with fewer and milder side-effects expected than current treatments. A method of screening therapeutics is described.

Abstract: A bioactive tissue scaffold is fabricated from glass fiber that forms a rigid three-dimensional porous matrix having a bioactive composition. Porosity in the form of interconnected pore space is provided by the pore space between the glass fiber in the porous matrix. Mechanical properties such as strength, elastic modulus, and pore size distribution is provided by the three-dimensional matrix that is formed by bonded overlapping and intertangled fibers. The bioactive tissue scaffold can be formed from raw materials that are not bioactive, but rather precursors to bioactive materials. The bioactive tissue scaffold supports tissue in-growth to provide osteoconductivity as a resorbable tissue scaffold, used for the repair of damaged and/or diseased bone tissue.

Abstract: The present invention provides biocide compositions, containing DBNPA encapsulated or absorbed in ceramic powders or xerogels, for preventing the formation of biofilms and for incorporating into paints, coatings, plasters, and plastics.

Abstract: A tablet having excellent disintegration properties, as a tableted product, for a long time and has excellent shape-retention stability by the improvement of the strength of the tablet. The antacid and laxative tablet comprises magnesium oxide particles as the main component, wherein (a) the average secondary particle diameter measured by a laser diffraction scattering method of the magnesium oxide particles is 0.5 to 10 ?m, (b) the content of the magnesium oxide particles is 85 to 96 wt %, (c) the content of crystalline cellulose as a binder is 2 to 8 wt %, (d) the content of croscarmellose sodium as a disintegrating agent-I is 0.8 to 2.5 wt %, (e) the content of insoluble polyvinyl pyrrolidone as a disintegrating agent-II is 1 to 3.5 wt %, and (f) the content of a lubricant is 0.5 to 2 wt %.

Abstract: Organic-inorganic composite particles includes inorganic oxide particles each of which has a cationic charge on the particle surface and polymer gel molecules which are derived from a natural substance, have an anionic functional group and one or more hydroxyl groups in a molecule and have both a shrinking and a swelling property, the polymer gel molecules are electrostatically bonded to surfaces of the inorganic oxide particles; a process for producing the particles; a dispersion containing the particles; and a cosmetic containing the particles. These organic-inorganic composite particles have good dispersibility not only in aqueous solvents such as water but also in non-aqueous solvents and further have characteristics that aggregation of the particles scarcely occurs.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage for in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavor; products, intermediate products, and uses thereof.

Abstract: A mineral mixture including at least' MgO and its equilibrium of Mg(OH)2, and MgCl2, in which MgO—Mg(OH)2 constitutes between 85 and 99.99% by weight; and MgCl2 constitutes between 0.01 and 15% by weight of the magnesium compounds in the mineral mixture. Preparations containing the salt mixture and the use of the mineral mixture for the production of a pharmaceutical preparation for the prevention or therapy of a condition, the condition being undesired eczema or psoriasis, are also described.

Abstract: Magnesium oxide granules which are excellent in dissolution property, are palatable, rarely leave any rough feeling in the oral cavity and have a good color in appearance. The granules comprise magnesium oxide particles which are represented by the following formula (1) and have an average secondary particle diameter of 0.1 to 25 ?m and an apparent specific volume of 3 to 20 ml/g, a sugar alcohol and a disintegrating agent. (Mg2+1-xZn2+x)O??(1) (In the formula, X is a numeral of 0 to 0.02.